Riso Pharmaceuticals International
Bioadvantex
Urixin
Silexin
Biolyse
Paclitaxel
BioSyent Inc.
FeraMAX
Feldan
Glenwood
Helsinn
Gelclair
Klean-Prep
Nasaleze Ltd.
Nasaleze
Omega laboratories
Pamidronate
PISA
Serral Laboratories
Stella Pharmaceutical Canada Inc.
Kolik-Gripe Water
Unigene
Fortical
 
Paclitaxel

 

Paclitaxel for Injection

Biolyse Pharma's Paclitaxel for Injection is an anti-cancer drug that has proven effective against breast and lung cancer in clinical testing. Biolyse developed the technology of extracting paclitaxel from Taxus canadensis, commonly known as the Canada Yew or ground hemlock, in such a manner that yields a large amount of biomass, without harming the plant itself. This ground-breaking technology provides Biolyse with a plentiful and renewable source of high-quality primary materials, and ensures that it will be able to make paclitaxel more available to the world market.

 
 

Riso Pharma Tech is a Canadian-based specialty pharmaceutical company focused on in-licensing late-stage and approved molecules for marketing and sales in Canada, certain European Union countries, Latin America, and the Middle East.

 

From large multi-national pharmaceutical companies to small biotechs, Riso's license deals have yielded successful product launches in its territories. Five regional offices and over 360 employees worldwide enable Riso to extend the reach of our partner companies' products.

 

With an extensive track record of greater than 10+ years marketing and sales success in its territories, and thanks to Riso's financial strength, Riso is aggressively pursuing new in-licensing opportunities across several therapeutic areas: oncology, supportive care, neurology, endocrinology and women's health.